Emodin, an anthraquinone derivative, has been reported to increase TNF-α, RIPK1, and RIPK3 levels in in vitro and in vivo glioma cancer models, which significantly inhibited glioma progression through necroptosis induction [263]. Here, RIPK1 is linked to central nervous system cancer.